RBF Capital’s Atea Pharmaceuticals AVIR Stock Holding History

RBF Capital’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$161K	Hold	30,000	–	–	0.01%	471
2025 Q4	$107K	Hold	30,000	–	–	﹤0.01%	536
2025 Q3	$87K	Hold	30,000	–	–	﹤0.01%	562
2025 Q2	$108K	Sell	30,000 -14,929	-33%	-$44.5K	0.01%	568
2025 Q1	$134K	Sell	44,929 -10,000	-18%	-$31.2K	0.01%	535
2024 Q4	$183K	Sell	54,929 -93,522	-63%	-$311K	0.01%	507
2024 Q3	$497K	Hold	148,451	–	–	0.02%	413
2024 Q2	$491K	Hold	148,451	–	–	0.03%	382
2024 Q1	$600K	Sell	148,451 -3,965	-3%	-$15.5K	0.03%	372
2023 Q4	$465K	Hold	152,416	–	–	0.03%	397
2023 Q3	$457K	Sell	152,416 -6,233	-4%	-$21.2K	0.03%	371
2023 Q2	$593K	Sell	158,649 -56,280	-26%	-$211K	0.04%	338
2023 Q1	$719K	Sell	214,929 -53,262	-20%	-$216K	0.05%	285
2022 Q4	$1.29M	Buy	+268,191	New	+$1.36M	0.1%	209

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

RBF Capital's AVIR Position: Q1 2026 in Review

RBF Capital held its Atea Pharmaceuticals (AVIR) position steady in Q1 2026 at 30,000 shares worth $161K. The position accounts for 0.01% of the portfolio, ranked #471.

RBF Capital first reported a position in AVIR in Q4 2022 and has held it in 14 quarters since. The position peaked at $1.29M in Q4 2022. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

RBF Capital held 30,000 shares of Atea Pharmaceuticals worth $161K as of Q1 2026.
RBF Capital left its Atea Pharmaceuticals share count unchanged in Q1 2026.
Atea Pharmaceuticals made up 0.01% of RBF Capital's portfolio in Q1 2026, its #471 holding.
RBF Capital first reported a position in Atea Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
RBF Capital's Atea Pharmaceuticals position peaked at $1.29M in Q4 2022.
127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on RBF Capital's 13F filing for Q1 2026, filed 15 May 2026.